Toll-Like Receptors in the Immunotherapy Era: Dual-Edged Swords of Tumor Immunity and Clinical Translation

Abstract

Toll-like receptors (TLRs), which are critical components of innate immunity, play a significant role in immune responses and deepen our understanding of TLRs. TLRs are a group of transmembrane proteins with similar structures distributed on the cell membrane and endosomes. They trigger downstream acute or chronic inflammatory responses by recognizing different types of pathogen-associated molecular patterns and damage-associated molecular patterns. TLRs play pivotal regulatory roles in various tumor types. Over the past few decades, research on TLRs has become increasingly popular, and these molecules can not only directly recognize tumor components as potential targets to activate antitumor immune responses but also act as accomplices to tumor progression and even as driver genes in certain tumor types. Despite their importance, the mechanisms underlying their dual functions remain poorly understood, creating a gap in current research. Here, we summarize the latest advancements in TLR signaling pathways and their application in tumor therapy in recent years, and highlight the development prospects and potential of TLRs in tumor therapy. Moreover, this review underscores the critical regulatory roles of TLRs across various tumor types and explores their prospects in oncology, offering valuable insights for developing targeted therapies and improving cancer outcomes.

Keywords

cancer / clinical translation / innate immunity / nuclear factor-κB / Toll-like receptor

References

[1] C. A. Janeway, “Approaching the Asymptote? Evolution and Revolution in Immunology,” Cold Spring Harbor Symposia on Quantitative Biology 54 Pt 1 (1989): 1-13.

[2] B. Lemaitre, E. Nicolas, L. Michaut, J. M. Reichhart, J. A. Hoffmann, “The Dorsoventral Regulatory Gene Cassette Spätzle/Toll/Cactus Controls the Potent Antifungal Response in Drosophila Adults,” Cell 86, no. 6 (1996): 973-83.

[3] S. Akira, S. Uematsu, O. Takeuchi, “Pathogen Recognition and Innate Immunity,” Cell 124, no. 4 (2006): 783-801.

[4] H. Guan, X. Chen, J. Liu, et al., “Molecular Characteristics and Therapeutic Implications of Toll-Like Receptor Signaling Pathway in Melanoma,” Scientific Reports 13, no. 1 (2023): 13788.

[5] J. Zindel, P. Kubes, “DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation,” Annual Review of Pathology 15 (2020): 493-518.

[6] H. M. Kim, B. S. Park, J. I. Kim, et al., “Crystal Structure of the TLR4-MD-2 Complex With Bound Endotoxin Antagonist Eritoran,” Cell 130, no. 5 (2007): 906-17.

[7] W. Ping, S. Hong, Y. Xun, C. Li, “Comprehensive Bioinformatics Analysis of Toll-Like Receptors (TLRs) in Pan-Cancer,” BioMed Research International 2022, no. 1 (2022): 4436646.

[8] N. J. Gay, M. Gangloff, “Structure and Function of Toll Receptors and Their Ligands,” Annual Review of Biochemistry 76 (2007): 141-65.

[9] L. Alexopoulou, A. C. Holt, R. Medzhitov, R. A. Flavell, “Recognition of Double-Stranded RNA and Activation of NF-κB by Toll-Like Receptor 3,” Nature 413, no. 6857 (2001): 732-8.

[10] M. Matsumoto, T. Seya, “TLR3: Interferon Induction by Double-Stranded RNA Including Poly(I:C),” Advanced Drug Delivery Reviews 60, no. 7 (2008): 805-12.

[11] K. Farhat, S. Riekenberg, H. Heine, et al., “Heterodimerization of TLR2 With TLR1 or TLR6 Expands the Ligand Spectrum but Does Not Lead to Differential Signaling,” Journal of Leukocyte Biology 83, no. 3 (2008): 692-701.

[12] A. K. Rout, V. Acharya, D. Maharana, et al., “Insights Into Structure and Dynamics of Extracellular Domain of Toll-Like Receptor 5 in Cirrhinus Mrigala (mrigala): A Molecular Dynamics Simulation Approach,” PLoS ONE 16, no. 1 (2021): e0245358.

[13] K. Maeda, S. Akira, “TLR7 Structure: Cut in Z-Loop,” Immunity 45, no. 4 (2016): 705-7.

[14] S. S. Diebold, T. Kaisho, H. Hemmi, S. Akira, C. Reis e Sousa, “Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA,” Science 303, no. 5663 (2004): 1529-31.

[15] D. H. Song, J. O. Lee, “Sensing of Microbial Molecular Patterns by Toll-Like Receptors,” Immunological Reviews 250, no. 1 (2012): 216-29.

[16] A. Hidmark, A. von Saint Paul, A. H. Dalpke, “Cutting Edge: TLR13 Is a Receptor for Bacterial RNA,” Journal of Immunology 189, no. 6 (2012): 2717-21.

[17] D. Fisch, T. Zhang, H. Sun, et al., “Molecular Definition of the Endogenous Toll-Like Receptor Signalling Pathways,” Nature 631, no. 8021 (2024): 635-44.

[18] Y. Liu, J. Yuan, Y. Zhang, et al., “OTUD5 Promotes the Inflammatory Immune Response by Enhancing MyD88 Oligomerization and Myddosome Formation,” Cell Death and Differentiation 31, no. 6 (2024): 753-67.

[19] S. N. Jia, Y. B. Han, R. Yang, Z. C. Yang, “Chemokines in Colon Cancer Progression,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 400-7.

[20] W. Li, F. Wang, R. Guo, Z. Bian, Y. Song, “Targeting Macrophages in Hematological Malignancies: Recent Advances and Future Directions,” Journal of Hematology & Oncology 15, no. 1 (2022): 110.

[21] S. Mukherjee, J. Bayry, “The Yin and Yang of TLR4 in COVID-19,” Cytokine & Growth Factor Reviews 82 (2025): 70-85.

[22] S. Mukherjee, S. Karmakar, S. P. S. Babu, “TLR2 and TLR4 Mediated Host Immune Responses in Major Infectious Diseases: A Review,” The Brazilian Journal of Infectious Diseases 20, no. 2 (2016): 193-204.

[23] J. W. Duess, M. E. Sampah, C. M. Lopez, et al., “Necrotizing Enterocolitis, Gut Microbes, and Sepsis,” Gut Microbes 15, no. 1 (2023): 2221470.

[24] A. J. M. Ferreri, T. Calimeri, K. Cwynarski, et al., “Primary Central Nervous System Lymphoma,” Nature Reviews Disease Primers 9, no. 1 (2023): 29.

[25] M. Arnaud, M. Loiselle, C. Vaganay, et al., “Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms,” Journal of the American Society of Nephrology 33, no. 6 (2022): 1154-71.

[26] P. Prabutzki, J. Schiller, K. M. Engel, “Phospholipid-Derived Lysophospholipids in (patho)Physiology,” Atherosclerosis 398 (2024): 118569.

[27] O. K. Dagher, R. D. Schwab, S. K. Brookens, A. D. Posey, “Advances in Cancer Immunotherapies,” Cell 186, no. 8 (2023): 1814-1814.e1.

[28] W. Ping, S. Hong, Y. Xun, C. Li, “Comprehensive Bioinformatics Analysis of Toll-Like Receptors (TLRs) in Pan-Cancer,” BioMed Research International 2022 (2022): 4436646.

[29] M. K. Vidya, V. G. Kumar, V. Sejian, M. Bagath, G. Krishnan, R. Bhatta, “Toll-Like Receptors: Significance, Ligands, Signaling Pathways, and Functions in Mammals,” International Reviews of Immunology 37, no. 1 (2018): 20-36.

[30] P. Weng, M. Lan, H. Zhang, et al., “Both IRAK3 and IRAK1 Activate the MyD88-TRAF6 Pathway in Zebrafish,” Journal of Immunology 213, no. 3 (2024): 362-72.

[31] M. Pereira, D. F. Durso, C. E. Bryant, et al., “The IRAK4 Scaffold Integrates TLR4-Driven TRIF and MYD88 Signaling Pathways,” Cell Reports 40, no. 7 (2022): 111225.

[32] C. E. Espada, C. St Gelais, S. Bonifati, et al., “TRAF6 and TAK1 Contribute to SAMHD1-Mediated Negative Regulation of NF-κB Signaling,” Journal of Virology 95, no. 3 (2021).

[33] Y. Shi, Y. Wu, L. Wang, et al., “Gooderoside A From Anoectochilus Elatus Attenuates Acute and Chronic Pains by Inhibiting NO/cGMP and IRAK4/IRAK1/TAK1 Signaling Pathways,” Journal of Ethnopharmacology 324 (2024): 117767.

[34] I. Gottschalk, U. Kölsch, D. L. Wagner, et al., “IRAK1 Duplication in MECP2 Duplication Syndrome Does Not Increase Canonical NF-κB-Induced Inflammation,” Journal of Clinical Immunology 43, no. 2 (2023): 421-39.

[35] M. Liu, Y. Ren, Z. Zhou, et al., “The Crosstalk Between Macrophages and Cancer Cells Potentiates Pancreatic Cancer Cachexia,” Cancer Cell 42, no. 5 (2024): 885-903.e4.

[36] Y. Li, J. Peng, Y. Xia, et al., “Sufu Limits Sepsis-Induced Lung Inflammation via Regulating Phase Separation of TRAF6,” Theranostics 13, no. 11 (2023): 3761-80.

[37] Y. Lv, K. Kim, Y. Sheng, et al., “YAP Controls Endothelial Activation and Vascular Inflammation Through TRAF6,” Circulation Research 123, no. 1 (2018): 43-56.

[38] F. Gao, J. Pang, M. Lu, et al., “Nile Tilapia TLR3 Recruits MyD88 and TRIF as Adaptors and Is Involved in the NF-κB Pathway in the Immune Response,” International Journal of Biological Macromolecules 218 (2022): 878-90.

[39] X. Jin, W. Dong, K. Chang, Y. Yan, “Research on the Signaling Pathways Related to the Intervention of Traditional Chinese Medicine in Parkinson's Disease: A Literature Review,” Journal of Ethnopharmacology 326 (2024): 117850.

[40] R. Ko, J. Seo, H. Park, N. Lee, S. Y. Lee, “Pim1 Promotes IFN-β Production by Interacting With IRF3,” Experimental & Molecular Medicine 54, no. 11 (2022): 2092-103.

[41] K. A. Fitzgerald, J. C. Kagan, “Toll-Like Receptors and the Control of Immunity,” Cell 180, no. 6 (2020): 1044-66.

[42] L. Yin, X. Li, J. Hou, “Macrophages in Periodontitis: A Dynamic Shift Between Tissue Destruction and Repair,” Japanese Dental Science Review 58 (2022): 336-47.

[43] J. Park, K. Lee, K. Kim, S. J. Yi, “The Role of Histone Modifications: From Neurodevelopment to Neurodiseases,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 217.

[44] L. Zhang, X. Xiao, P. R. Arnold, X. C. Li, “Transcriptional and Epigenetic Regulation of Immune Tolerance: Roles of the NF-κB Family Members,” Cellular & Molecular Immunology 16, no. 4 (2019): 315-23.

[45] J. Liao, J. Ho, M. Burns, E. C. Dykhuizen, D. C. Hargreaves, “Collaboration Between Distinct SWI/SNF Chromatin Remodeling Complexes Directs Enhancer Selection and Activation of Macrophage Inflammatory Genes,” Immunity 57, no. 8 (2024): 1780-95.e6.

[46] H. A. Malone, C. W. M. Roberts, “Chromatin Remodellers as Therapeutic Targets,” Nature Reviews Drug Discovery 23, no. 9 (2024): 661-81.

[47] A. C. Feng, B. J. Thomas, P. K. Purbey, et al., “The Transcription Factor NF-κB Orchestrates Nucleosome Remodeling During the Primary Response to Toll-Like Receptor 4 Signaling,” Immunity 57, no. 3 (2024): 462-77.e9.

[48] M. A. Frederick, K. E. Williamson, M. Fernandez Garcia, et al., “A Pioneer Factor Locally Opens Compacted Chromatin to Enable Targeted ATP-Dependent Nucleosome Remodeling,” Nature Structural & Molecular Biology 30, no. 1 (2023): 31-7.

[49] N. Okuma, M. A. Ito, T. Shimizu, et al., “Amplification of Poly(I:C)-Induced Interleukin-6 Production in Human Bronchial Epithelial Cells by Priming With Interferon-γ,” Scientific Reports 13, no. 1 (2023): 21067.

[50] Y. Abe, E. R. Kofman, Z. Ouyang, et al., “A TLR4/TRAF6-Dependent Signaling Pathway Mediates NCoR Coactivator Complex Formation for Inflammatory Gene Activation,” PNAS 121, no. 2 (2024): e2316104121.

[51] J. Zou, S. Anai, S. Ota, S. Ishitani, M. Oginuma, T. Ishitani, “Determining Zebrafish Dorsal Organizer Size by a Negative Feedback Loop Between Canonical/Non-Canonical Wnts and Tlr4/NFκB,” Nature Communications 14, no. 1 (2023): 7194.

[52] Y. Wu, Q. Wang, M. Li, et al., “SLAMF7 Regulates the Inflammatory Response in Macrophages During Polymicrobial Sepsis,” Journal of Clinical Investigation 133, no. 6 (2023): e150224.

[53] U. Choe, Q. Pham, Y. S. Kim, L. Yu, T. T. Y. Wang, “Identification and Elucidation of Cross Talk Between SLAM Family Member 7 (SLAMF7) and Toll-Like Receptor (TLR) Pathways in Monocytes and Macrophages,” Scientific Reports 13, no. 1 (2023): 11007.

[54] L. Zhang, D. Cheng, J. Zhang, et al., “Role of Macrophage AHR/TLR4/STAT3 Signaling Axis in the Colitis Induced by Non-Canonical AHR Ligand Aflatoxin B1,” Journal of Hazardous Materials 452 (2023): 131262.

[55] W. Bi, K. Bao, X. Zhou, et al., “PSMC5 Regulates Microglial Polarization and Activation in LPS-Induced Cognitive Deficits and Motor Impairments by Interacting With TLR4,” Journal of Neuroinflammation 20, no. 1 (2023): 277.

[56] J. Bekampytė, A. Savukaitytė, A. Bartnykaitė, et al., “TIRAP Rs8177376, Rs611953, Rs3802814, and Rs8177374 Polymorphisms and Their Association With Cervical Cancer Phenotype and Prognosis,” Genes (Basel) 13, no. 8 (2022): 1365.

[57] P. K. Purbey, J. Seo, M. K. Paul, et al., “Opposing Tumor-Cell-Intrinsic and -Extrinsic Roles of the IRF1 Transcription Factor in Antitumor Immunity,” Cell Reports 43, no. 6 (2024): 114289.

[58] L. Zhang, X. Wei, Z. Wang, et al., “NF-κB Activation Enhances STING Signaling by Altering Microtubule-Mediated STING Trafficking,” Cell Reports 42, no. 3 (2023): 112185.

[59] Z. Magri, D. Jetton, H. I. Muendlein, et al., “CD14 is a Decision-Maker Between Fas-Mediated Death and Inflammation,” Cell Reports 43, no. 9 (2024): 114685.

[60] H. I. Muendlein, W. M. Connolly, J. Cameron, et al., “Neutrophils and Macrophages Drive TNF-Induced Lethality via TRIF/CD14-Mediated Responses,” Science Immunology 7, no. 78 (2022): eadd0665.

[61] K. J. Ishii, S. Koyama, A. Nakagawa, C. Coban, S. Akira, “Host Innate Immune Receptors and Beyond: Making Sense of Microbial Infections,” Cell Host & Microbe 3, no. 6 (2008): 352-63.

[62] N. D. Udeshi, C. Xu, Z. Jiang, et al., “Cell-Surface Milieu Remodeling in Human Dendritic Cell Activation,” Journal of Immunology 213, no. 7 (2024): 1023-32.

[63] A. Novak, E. Pupo, E. Van't Veld, V. Rutten, F. Broere, A. Sloots, “Activation of Canine, Mouse and Human TLR2 and TLR4 by Inactivated Leptospira Vaccine Strains,” Frontiers in Immunology 13 (2022): 823058.

[64] H. Bao, Z. Gong, J. Zhao, et al., “Prostaglandin D(2) Is Involved in the Regulation of Inflammatory Response in Staphylococcus Aureus-Infected Mice Macrophages,” International Immunopharmacology 129 (2024): 111526.

[65] Y. Zhang, X. Liang, X. Bao, W. Xiao, G. Chen, “Toll-Like Receptor 4 (TLR4) Inhibitors: Current Research and Prospective,” European Journal of Medicinal Chemistry 235 (2022): 114291.

[66] B. M. Tiemeijer, S. Heester, A. Y. W. Sturtewagen, A. Smits, J. Tel, “Single-Cell Analysis Reveals TLR-Induced Macrophage Heterogeneity and Quorum Sensing Dictate Population Wide Anti-Inflammatory Feedback in Response to LPS,” Frontiers in Immunology 14 (2023): 1135223.

[67] S. Y. Zhang, Q. P. Xu, L. N. Shi, et al., “Soluble CD4 Effectively Prevents Excessive TLR Activation of Resident Macrophages in the Onset of Sepsis,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 236.

[68] Z. Sun, Q. Liu, Z. Lv, et al., “Targeting Macrophagic SHP2 for Ameliorating Osteoarthritis via TLR Signaling,” Acta Pharmaceutica Sinica B 12, no. 7 (2022): 3073-84.

[69] S. Guo, J. Zhang, Q. Zhang, et al., “Polygala Tenuifolia Willd. Extract Alleviates LPS-Induced Acute Lung Injury in Rats via TLR4/NF-κB Pathway and NLRP3 Inflammasome Suppression,” Phytomedicine 132 (2024): 155859.

[70] K. Sakaniwa, A. Fujimura, T. Shibata, et al., “TLR3 Forms a Laterally Aligned Multimeric Complex Along Double-Stranded RNA for Efficient Signal Transduction,” Nature Communications 14, no. 1 (2023): 164.

[71] I. Martínez-Espinoza, A. Guerrero-Plata, “The Relevance of TLR8 in Viral Infections,” Pathogens 11, no. 2 (2022): 134.

[72] M. Shafeghat, S. Kazemian, A. Aminorroaya, Z. Aryan, N. Rezaei, “Toll-Like Receptor 7 Regulates Cardiovascular Diseases,” International Immunopharmacology 113, no. Pt A (2022): 109390.

[73] S. Zhang, X. Cao, “TLR9 Triggers MyD88-Independent Anti-Inflammatory Signaling in Lupus,” Trends in Immunology 44, no. 3 (2023): 153-5.

[74] P. Wang, X. Yang, L. Zhang, et al., “Tlr9 Deficiency in B Cells Leads to Obesity by Promoting Inflammation and Gut Dysbiosis,” Nature Communications 15, no. 1 (2024): 4232.

[75] S. R. P. Kumar, M. Biswas, D. Cao, et al., “TLR9-Independent CD8(+) T Cell Responses in Hepatic AAV Gene Transfer Through IL-1R1-MyD88 Signaling,” Molecular Therapy 32, no. 2 (2024): 325-39.

[76] M. A. Miles, R. Luong, E. E. To, et al., “TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development,” Cells 13, no. 1 (2024): 97.

[77] C. Rizzello, V. Cancila, S. Sangaletti, et al., “Intracellular Osteopontin Protects From Autoimmunity-Driven Lymphoma Development Inhibiting TLR9-MYD88-STAT3 Signaling,” Molecular Cancer 21, no. 1 (2022): 215.

[78] A. Knight, L. Karapetyan, J. M. Kirkwood, “Immunotherapy in Melanoma: Recent Advances and Future Directions,” Cancers (Basel) 15, no. 4 (2023): 1106.

[79] J. Litak, M. Mazurek, C. Grochowski, P. Kamieniak, J. Roliński, “PD-L1/PD-1 Axis in Glioblastoma Multiforme,” International Journal of Molecular Sciences 20, no. 21 (2019): 5347.

[80] D. Chi, W. Xu, X. Tao, T. Zhang, Y. Cui, “PD-L1 Expression in Colorectal Cancer and Its Relationship With TLR-4 Expression,” Journal of B.U.ON. 25, no. 3 (2020): 1423-9.

[81] Y. Wang, J. Liu, X. Yang, et al., “Bacillus Calmette-Guérin and Anti-PD-L1 Combination Therapy Boosts Immune Response Against Bladder Cancer,” OncoTargets and Therapy 11 (2018): 2891-9.

[82] M. Rodríguez-García, F. Porichis, O. G. de Jong, et al., “Expression of PD-L1 and PD-L2 on Human Macrophages Is Up-Regulated by HIV-1 and Differentially Modulated by IL-10,” Journal of Leukocyte Biology 89, no. 4 (2011): 507-15.

[83] G. Sinos, D. Schizas, A. Kapelouzou, et al., “The Novel Role of the Expression of Toll-Like Receptors TLR-5, TLR-6, and TLR-9 and Associated up-Regulation of Programmed Cell Death 1 Receptor (PD-1) and Its Ligand (PD-L1) in Lung Sepsis,” International Journal of Molecular Sciences 26, no. 5 (2025): 2274.

[84] L. Ma, N. Qin, W. Wan, et al., “TLR9 Activation Induces Immunosuppression and Tumorigenesis via PARP1/PD-L1 Signaling Pathway in Oral Squamous Cell Carcinoma,” American Journal of Physiology. Cell Physiology 326, no. 2 (2024): C362-C81.

[85] L. Fernandez-Rodriguez, C. Cianciaruso, R. Bill, et al., “Dual TLR9 and PD-L1 Targeting Unleashes Dendritic Cells to Induce Durable Antitumor Immunity,” Journal for ImmunoTherapy of Cancer 11, no. 5 (2023): e006714.

[86] M. S. Gilardini Montani, R. Santarelli, L. Falcinelli, et al., “EBV Up-Regulates PD-L1 on the Surface of Primary Monocytes by Increasing ROS and Activating TLR Signaling and STAT3,” Journal of Leukocyte Biology 104, no. 4 (2018): 821-32.

[87] P. Behzadi, H. A. García-Perdomo, T. M. Karpiński, “Toll-Like Receptors: General Molecular and Structural Biology,” Journal of Immunology Research 2021 (2021): 9914854.

[88] Aga, M. Banday, S. Nissar. Genetic Polymorphism and Disease. CRC Press, 2022.

[89] S. Mukherjee, S. Huda, S. P. Sinha Babu, “Toll-Like Receptor Polymorphism in Host Immune Response to Infectious Diseases: A Review,” Scandinavian Journal of Immunology 90, no. 1 (2019): e12771.

[90] P. Behzadi, D. Chandran, C. Chakraborty, et al., “The Dual Role of Toll-Like Receptors in COVID-19: Balancing Protective Immunity and Immunopathogenesis,” International Journal of Biological Macromolecules 284, no. Pt 2 (2025): 137836.

[91] P. Behzadi. “The Role of Toll-Like Receptor (TLR) Polymorphisms in Urinary Bladder Cancer,” Springer eBooks, (2021), 281-317

[92] P. Behzadi, C. H. Kim, E. A. Pawlak, A. Algammal, “Editorial: The Innate and Adaptive Immune System in Human Urinary System,” Frontiers in Immunology 14 (2023): 1294869.

[93] P. Behzadi, A. S. Sameer, S. Nissar, et al., “The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs),” Journal of Immunology Research 2022 (2022): 2054431.

[94] S. Ohadian Moghadam, M. R. Nowroozi, “Toll-Like Receptors: The Role in Bladder Cancer Development, Progression and Immunotherapy,” Scandinavian Journal of Immunology 90, no. 6 (2019): e12818.

[95] P. Gao, H. Liu, H. Huang, et al., “The Crohn Disease-Associated ATG16L1(T300A) Polymorphism Regulates Inflammatory Responses by Modulating TLR- and NLR-Mediated Signaling,” Autophagy 18, no. 11 (2022): 2561-75.

[96] D. Menendez, J. Snipe, J. Marzec, et al., “p53-Responsive TLR8 SNP Enhances Human Innate Immune Response to Respiratory Syncytial Virus,” Journal of Clinical Investigation 129, no. 11 (2019): 4875-84.

[97] D. Menendez, J. M. Lowe, J. Snipe, M. A. Resnick, “Ligand Dependent Restoration of Human TLR3 Signaling and Death in p53 Mutant Cells,” Oncotarget 7, no. 38 (2016): 61630-42.

[98] M. Shatz, I. Shats, D. Menendez, M. A. Resnick, “p53 Amplifies Toll-Like Receptor 5 Response in Human Primary and Cancer Cells Through Interaction With Multiple Signal Transduction Pathways,” Oncotarget 6, no. 19 (2015): 16963-80.

[99] K. D. Kania, D. Haręża, J. R. Wilczyński, et al., “The Toll-Like Receptor 4 Polymorphism Asp299Gly Is Associated With an Increased Risk of Ovarian Cancer,” Cells 11, no. 19 (2022): 3137.

[100] A. Jha, N. Nath, A. Kumari, N. Kumari, A. K. Panda, R. Mishra, “Polymorphisms and Haplotypes of TLR-4/9 Associated With Bacterial Infection, Gingival Inflammation/Recession and Oral Cancer,” Pathology, Research and Practice 241 (2023): 154284.

[101] I. Sghaier, S. Zidi, L. Mouelhi, et al., “TLR3 and TLR4 SNP Variants in the Liver Disease Resulting From Hepatitis B Virus and Hepatitis C Virus Infection,” British Journal of Biomedical Science 76, no. 1 (2019): 35-41.

[102] T. Xu, D. Fu, Y. Ren, et al., “Genetic Variations of TLR5 Gene Interacted With Helicobacter Pylori Infection Among Carcinogenesis of Gastric Cancer,” Oncotarget 8, no. 19 (2017): 31016-22.

[103] S. Mukherjee, N. Joardar, S. Sengupta, S. P. Sinha Babu, “Gut Microbes as Future Therapeutics in Treating Inflammatory and Infectious Diseases: Lessons From Recent Findings,” The Journal of Nutritional Biochemistry 61 (2018): 111-28.

[104] M. E. Caetano-Silva, A. Shrestha, A. F. Duff, et al., “Aging Amplifies a Gut Microbiota Immunogenic Signature Linked to Heightened Inflammation,” Aging Cell 23, no. 8 (2024): e14190.

[105] A. Nabavi-Rad, A. Sadeghi, H. Asadzadeh Aghdaei, A. Yadegar, S. M. Smith, M. R. Zali, “The Double-Edged Sword of Probiotic Supplementation on Gut Microbiota Structure in Helicobacter Pylori Management,” Gut Microbes 14, no. 1 (2022): 2108655.

[106] L. Gul, D. Modos, S. Fonseca, et al., “Extracellular Vesicles Produced by the Human Commensal Gut Bacterium Bacteroides Thetaiotaomicron Affect Host Immune Pathways in a Cell-Type Specific Manner That Are Altered in Inflammatory Bowel Disease,” Journal of Extracellular Vesicles 11, no. 1 (2022): e12189.

[107] A. Adugna, Y. Muche, M. Jemal, S. D. Habtegiorgis, H. Belew, G. Azanaw Amare, “Gut Microbes as Medical Signature for the Effectiveness of Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer,” Aging Medicine (Milton) 7, no. 1 (2024): 121-30.

[108] S. Frosali, D. Pagliari, G. Gambassi, R. Landolfi, F. Pandolfi, R. Cianci, “How the Intricate Interaction Among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology,” Journal of Immunology Research 2015 (2015): 489821.

[109] D. Toor, M. K. Wsson, P. Kumar, et al., “Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases,” International Journal of Molecular Sciences 20, no. 10 (2019): 2432.

[110] J. Yiqian, Z. Xibin, P. U. Wenyuan, Z. Chunxiang, “Sanwu Baisan Decoction Inhibits Colorectal Cancer Progression in Mice by Remodeling Gut Microbiota and Tumorigenesis,” Journal of Traditional Chinese Medicine 43, no. 3 (2023): 466-73.

[111] M. Majewski, P. Mertowska, S. Mertowski, K. Torres, E. Grywalska, “How Toll-Like Receptor 9 Plays a Key Role in the Development of Gastric Cancer and Is Linked to Epstein-Barr Virus Infection,” Cancers (Basel) 15, no. 20 (2023): 5104.

[112] M. Liu, Z. Hu, C. Wang, Y. Zhang, “The TLR/MyD88 Signalling Cascade in Inflammation and Gastric Cancer: The Immune Regulatory Network of Helicobacter Pylori,” Journal of Molecular Medicine (Berl) 101, no. 7 (2023): 767-81.

[113] M. Cavaleiro-Pinto, B. Peleteiro, N. Lunet, H. Barros, “Helicobacter Pylori Infection and Gastric Cardia Cancer: Systematic Review and Meta-Analysis,” Cancer Causes & Control 22, no. 3 (2011): 375-87.

[114] S. Hansen, S. E. Vollset, M. H. Derakhshan, et al., “Two Distinct Aetiologies of Cardia Cancer; Evidence From Premorbid Serological Markers of Gastric Atrophy and Helicobacter Pylori Status,” Gut 56, no. 7 (2007): 918-25.

[115] I. Messaritakis, A. Koulouridi, E. Boukla, et al., “Investigation of Microbial Translocation, TLR and VDR Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients,” Cancers (Basel) 14, no. 18 (2022): 4407.

[116] B. Liu, Z. Zhou, Y. Jin, et al., “Hepatic Stellate Cell Activation and Senescence Induced by Intrahepatic Microbiota Disturbances Drive Progression of Liver Cirrhosis Toward Hepatocellular Carcinoma,” Journal for ImmunoTherapy of Cancer 10, no. 1 (2022): e003069.

[117] S. Li, H. Xia, Z. Wang, et al., “Intratumoral Microbial Heterogeneity Affected Tumor Immune Microenvironment and Determined Clinical Outcome of HBV-Related HCC,” Hepatology 78, no. 4 (2023): 1079-91.

[118] B. Paul, M. Lewinska, J. B. Andersen, “Lipid Alterations in Chronic Liver Disease and Liver Cancer,” JHEP Reports 4, no. 6 (2022): 100479.

[119] M. Pan, M. Luo, L. Liu, et al., “EGR1 Suppresses HCC Growth and Aerobic Glycolysis by Transcriptionally Downregulating PFKL,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 35.

[120] Y. Du, J. Wu, J. Liu, X. Zheng, D. Yang, M. Lu, “Toll-Like Receptor-Mediated Innate Immunity Orchestrates Adaptive Immune Responses in HBV Infection,” Frontiers in Immunology 13 (2022): 965018.

[121] M. Michelet, D. Alfaiate, B. Chardès, et al., “Inducers of the NF-κB Pathways Impair Hepatitis Delta Virus Replication and Strongly Decrease Progeny Infectivity in Vitro,” JHEP Reports 4, no. 3 (2022): 100415.

[122] M. E. H. Kayesh, M. Kohara, K. Tsukiyama-Kohara, “TLR Agonists as Vaccine Adjuvants in the Prevention of Viral Infections: An Overview,” Frontiers in Microbiology 14 (2023): 1249718.

[123] H. You, S. Qin, F. Zhang, et al., “Regulation of Pattern-Recognition Receptor Signaling by HBX During Hepatitis B Virus Infection,” Frontiers in Immunology 13 (2022): 829923.

[124] S. Kalita, M. J. Kalita, G. Hazarika, et al., “Altered Expression of Endosomal Toll-Like Receptors and HBeAg Seropositivity May Act Synergistically Towards the Vertical Transmission of HBV,” American Journal of Reproductive Immunology 90, no. 2 (2023): e13747.

[125] S. Y. Qi, M. M. Yang, C. Y. Li, K. Yu, S. L. Deng, “The HPV Viral Regulatory Mechanism of TLRs and the Related Treatments for HPV-Associated Cancers,” Frontiers in Immunology 15 (2024): 1407649.

[126] F. C. Gomes, D. D. R. Galhardo, A. C. G. Navegante, et al., “Bioinformatics Analysis to Identify the Relationship Between Human Papillomavirus-Associated Cervical Cancer, Toll-Like Receptors and Exomes: A Genetic Epidemiology Study,” PLoS ONE 19, no. 8 (2024): e0305760.

[127] M. Fracella, G. Oliveto, L. Sorrentino, et al., “Common Microbial Genital Infections and Their Impact on the Innate Immune Response to HPV in Cervical Cells,” Pathogens 11, no. 11 (2022): 1361.

[128] M. G. Morale, R. E. Tamura, R. Cintra, N. M. Araújo, L. L. Villa, “TLR4 and SARM1 Modulate Survival and Chemoresistance in an HPV-Positive Cervical Cancer Cell Line,” Scientific Reports 12, no. 1 (2022): 6714.

[129] W. Xu, Y. Lai, Y. Pan, et al., “m6A RNA Methylation-Mediated NDUFA4 Promotes Cell Proliferation and Metabolism in Gastric Cancer,” Cell Death & Disease 13, no. 8 (2022): 715.

[130] M. Kos, K. Bojarski, P. Mertowska, et al., “Immunological Strategies in Gastric Cancer: How Toll-Like Receptors 2, -3, -4, and -9 on Monocytes and Dendritic Cells Depend on Patient Factors?,” Cells 13, no. 20 (2024).

[131] X. Huang, Z. Ma, W. Qin, “Screening and Bioinformatics Analyses of Key miRNAs Associated With Toll-Like Receptor Activation in Gastric Cancer Cells,” Medicina (Kaunas, Lithuania) 59, no. 3 (2023): 511.

[132] A. Al Othaim, S. I. S. Al-Hawary, H. O. Alsaab, et al., “Common Variants in Toll-Like Receptor Family Genes and Risk of Gastric Cancer: A Systematic Review and Meta-Analysis,” Frontiers in Genetics 14 (2023): 1280051.

[133] X. Zhang, Y. He, X. Zhang, et al., “Sustained Exposure to Helicobacter Pylori Induces Immune Tolerance by Desensitizing TLR6,” Gastric Cancer 27, no. 2 (2024): 324-42.

[134] D. Sikora, J. Kiś, E. Stępień, B. Drop, M. Polz-Dacewicz, “Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status,” International Journal of Molecular Sciences 25, no. 16 (2024): 9053.

[135] P. Mertowska, K. Smolak, S. Mertowski, E. Grywalska, “Unraveling the Role of Toll-Like Receptors in the Immunopathogenesis of Selected Primary and Secondary Immunodeficiencies,” Cells 12, no. 16 (2023): 2055.

[136] J. Zhang, Y. Peng, Y. He, et al., “GPX1-Associated Prognostic Signature Predicts Poor Survival in Patients With Acute Myeloid Leukemia and Involves in Immunosuppression,” Biochim Biophys Acta Mol Basis Dis 1868, no. 1 (2022): 166268.

[137] F. Yu, Y. Chen, M. Zhou, et al., “Generation of a New Therapeutic D-Peptide That Induces the Differentiation of Acute Myeloid Leukemia Cells Through a TLR-2 Signaling Pathway,” Cell Death Discovery 10, no. 1 (2024): 51.

[138] H. A. Gamlen, J. S. Romer-Seibert, M. E. Lawler, et al., “miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML,” Clinical Cancer Research 28, no. 20 (2022): 4574-86.

[139] M. Qasim Mohammed, A. Hussein Alwan, A. Amer Almukhtar, M. Kareem Aneed Al-Saedi, “Revealing of TLR-9 Gene Polymorphisms by qPCR HRM Technique and Their Influence on TLR-9 Serum Level in Acute Myeloid Leukemia Patients: Case-Control Study,” Cytokine 182 (2024): 156730.

[140] P. Ekchariyawat, R. Saengfak, S. Sanongkiet, et al., “ECDD-S16 Targets Vacuolar ATPase: A Potential Inhibitor Compound for Pyroptosis-Induced Inflammation,” PLoS ONE 18, no. 11 (2023): e0292340.

[141] M. Hallek, T. D. Shanafelt, B. Eichhorst, “Chronic Lymphocytic Leukaemia,” Lancet 391, no. 10129 (2018): 1524-37.

[142] M. E. Mantione, M. Meloni, I. Sana, et al., “Disrupting Pro-Survival and Inflammatory Pathways With Dimethyl Fumarate Sensitizes Chronic Lymphocytic Leukemia to Cell Death,” Cell Death & Disease 15, no. 3 (2024): 224.

[143] D. E. Spaner, T. Y. Luo, G. Wang, G. Schreiber, D. Harari, Y. Shi, “Paradoxical Activation of Chronic Lymphocytic Leukemia Cells by Ruxolitinib in Vitro and in Vivo,” Frontiers in Oncology 13 (2023): 1043694.

[144] C. Martines, S. Chakraborty, M. Vujovikj, et al., “Macrophage- and BCR-Derived but Not TLR-Derived Signals Support the Growth of CLL and Richter Syndrome Murine Models in Vivo,” Blood 140, no. 22 (2022): 2335-47.

[145] P. M. Bruch, H. A. Giles, C. Kolb, et al., “Drug-Microenvironment Perturbations Reveal Resistance Mechanisms and Prognostic Subgroups in CLL,” Molecular Systems Biology 18, no. 8 (2022): e10855.

[146] I. Sana, M. E. Mantione, M. Meloni, et al., “Dimethyl Itaconate Selectively Targets Inflammatory and Metabolic Pathways in Chronic Lymphocytic Leukemia,” European Journal of Immunology 53, no. 10 (2023): e2350418.

[147] J. R. Hirsiger, A. Tzankov, I. Alborelli, et al., “Case Report: mRNA Vaccination-Mediated STAT3 Overactivation With Agranulocytosis and Clonal T-LGL Expansion,” Frontiers in Immunology 14 (2023): 1087502.

[148] V. C. Gibouin, M. Durand, C. Boudesco, et al., “First-in-Class Inhibitor of HSP110 Blocks BCR Activation Through SYK Phosphorylation in Diffuse Large B-Cell Lymphoma,” Leukemia 38, no. 8 (2024): 1742-50.

[149] M. Nakagawa, A. L. Shaffer III, M. Ceribelli, et al., “Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma,” Cancer Cell 34, no. 2 (2018): 286-97.e10.

[150] S. B. Shah, C. R. Carlson, K. Lai, et al., “Combinatorial Treatment Rescues Tumour-Microenvironment-Mediated Attenuation of MALT1 Inhibitors in B-Cell Lymphomas,” Nature Materials 22, no. 4 (2023): 511-23.

[151] M. J. Kim, J. Y. Kim, J. H. Shin, et al., “FFAR2 Antagonizes TLR2- and TLR3-Induced Lung Cancer Progression via the Inhibition of AMPK-TAK1 Signaling Axis for the Activation of NF-κB,” Cell & Bioscience 13, no. 1 (2023): 102.

[152] P. Neuperger, K. Szalontai, N. Gémes, et al., “Single-Cell Mass Cytometric Analysis of Peripheral Immunity and Multiplex Plasma Marker Profiling of Non-Small Cell Lung Cancer Patients Receiving PD-1 Targeting Immune Checkpoint Inhibitors in Comparison With Platinum-Based Chemotherapy,” Frontiers in Immunology 14 (2023): 1243233.

[153] N. Gémes, J. Balog, P. Neuperger, et al., “Single-Cell Immunophenotyping Revealed the Association of CD4+ Central and CD4+ Effector Memory T Cells Linking Exacerbating Chronic Obstructive Pulmonary Disease and NSCLC,” Frontiers in Immunology 14 (2023): 1297577.

[154] W. V. Velasco, N. Khosravi, S. Castro-Pando, et al., “Toll-Like Receptors 2, 4, and 9 Modulate Promoting Effect of COPD-Like Airway Inflammation on K-ras-Driven Lung Cancer Through Activation of the MyD88/NF-ĸB Pathway in the Airway Epithelium,” Frontiers in Immunology 14 (2023): 1118721.

[155] J. Y. Kim, J. H. Shin, M. J. Kim, et al., “PTK2 is a Potential Biomarker and Therapeutic Target for EGFR- or TLRs-Induced Lung Cancer Progression via the Regulation of the Cross-Talk Between EGFR- and TLRs-Mediated Signals,” Biomarker Research 12, no. 1 (2024): 52.

[156] L. Lin, Z. Guo, E. He, et al., “SIRT2 Regulates Extracellular Vesicle-Mediated Liver-Bone Communication,” Nature Metabolism 5, no. 5 (2023): 821-41.

[157] M. Wu, J. B. Zhang, Y. W. Xiong, et al., “Promotion of Lung Cancer Metastasis by SIRT2-Mediated Extracellular Protein Deacetylation,” Advanced Science (Weinh) 10, no. 3 (2023): e2205462.

[158] J. Y. Kim, J. H. Shin, M. J. Kim, et al., “β-Arrestin 2 Negatively Regulates Lung Cancer Progression by Inhibiting the TRAF6 Signaling Axis for NF-κB Activation and Autophagy Induced by TLR3 and TLR4,” Cell Death & Disease 14, no. 7 (2023): 422.

[159] N. H. Eisa, E. Said, A. E. Khodir, et al., “Effect of Diacerein on HOTAIR/IL-6/STAT3, Wnt/β-Catenin and TLR-4/NF-κB/TNF-α Axes in Colon Carcinogenesis,” Environmental Toxicology and Pharmacology 95 (2022): 103943.

[160] H. Feng, Z. Guo, X. Chen, et al., “Excessive HSP70/TLR2 Activation Leads to Remodeling of the Tumor Immune Microenvironment to Resist Chemotherapy Sensitivity of mFOLFOX in Colorectal Cancer,” Clinical Immunology 245 (2022): 109157.

[161] X. Ma, J. Su, S. Zhao, et al., “CCL3 Promotes Proliferation of Colorectal Cancer Related With TRAF6/NF-κB Molecular Pathway,” Contrast Media & Molecular Imaging 2022 (2022): 2387192.

[162] P. Bhamidipati, G. P. Nagaraju, R. Malla, “Immunoglobulin-Binding Protein and Toll-Like Receptors in Immune Landscape of Breast Cancer,” Life Sciences 358 (2024): 123196.

[163] Y. Choi, S. A. Kim, H. Jung, et al., “Novel Insights Into Paclitaxel's Role on Tumor-Associated Macrophages in Enhancing PD-1 Blockade in Breast Cancer Treatment,” Journal for ImmunoTherapy of Cancer 12, no. 7 (2024): e008864.

[164] C. Liedtke, C. Mazouni, K. R. Hess, et al., “Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer,” Journal of Clinical Oncology 41, no. 10 (2023): 1809-15.

[165] R. Taguchi, M. Yamaguchi-Tanaka, K. Takagi, et al., “Clinicopathological Significance and Prognostic Role of High Mobility Group Box 1 (HMGB1), Toll-Like Receptor (TLR) 2 and TLR4 in Breast Cancer,” Acta Histochem Cytochem 57, no. 2 (2024): 75-83.

[166] R. Blazquez, H. N. Chuang, B. Wenske, et al., “Intralesional TLR4 Agonist Treatment Strengthens the Organ Defense Against Colonizing Cancer Cells in the Brain,” Oncogene 41, no. 46 (2022): 5008-19.

[167] F. G. Özbay Kurt, B. A. Cicortas, B. M. Balzasch, et al., “S100A9 and HMGB1 Orchestrate MDSC-Mediated Immunosuppression in Melanoma Through TLR4 Signaling,” Journal for ImmunoTherapy of Cancer 12, no. 9 (2024): e009552.

[168] C. Bergmann, A. Poli, I. Agache, et al., “AllergoOncology: Danger Signals in Allergology and Oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper,” Allergy 77, no. 9 (2022): 2594-617.

[169] A. M. Nurmi, J. Hagström, H. Mustonen, H. Seppänen, C. Haglund, “The Expression and Prognostic Value of Toll-Like Receptors (TLRs) in Pancreatic Cancer Patients Treated With Neoadjuvant Therapy,” PLoS ONE 17, no. 5 (2022): e0267792.

[170] P. Che, S. Jiang, W. Zhang, H. Zhu, D. Hu, D. Wang, “A Comprehensive Gene Expression Profile Analysis of Prostate Cancer Cells Resistant to Paclitaxel and the Potent Target to Reverse Resistance,” Human & Experimental Toxicology 41 (2022): 9603271221129854.

[171] L. O. Reis, A. C. C. Salustiano, D. M. Capibaribe, I. G. A. Kiehl, F. Denardi, “Castration Immunoregulates Toll-Like Receptor-4 in Male Bladder Cancer,” International Urology and Nephrology 54, no. 11 (2022): 2845-53.

[172] S. Davakis, A. Kapelouzou, S. Sakellariou, et al., “Clinical and Oncological Impact of the Toll-Like Receptor-3 and -4 in Esophageal and Gastro-Esophageal Junction Adenocarcinoma,” Anticancer Research 43, no. 7 (2023): 3183-91.

[173] H. Liang, L. Zhang, Z. Liu, et al., “Upregulation of TLR5 Indicates a Favorable Prognosis in Prostate Cancer,” Prostate 83, no. 11 (2023): 1035-45.

[174] B. Liu, Y. Sun, T. Geng, et al., “C5AR1-Induced TLR1/2 Pathway Activation Drives Proliferation and Metastasis in Anaplastic Thyroid Cancer,” Molecular Carcinogenesis 63, no. 10 (2024): 1938-52.

[175] Y. Deng, J. Yang, J. Qian, et al., “TLR1/TLR2 Signaling Blocks the Suppression of Monocytic Myeloid-Derived Suppressor Cell by Promoting Its Differentiation Into M1-Type Macrophage,” Molecular Immunology 112 (2019): 266-73.

[176] K. C. Huang, T. W. Ke, J. Y. Chen, et al., “Dysfunctional TLR1 Reduces the Therapeutic Efficacy of Chemotherapy by Attenuating HMGB1-Mediated Antitumor Immunity in Locally Advanced Colorectal Cancer,” Scientific Reports 13, no. 1 (2023): 19440.

[177] H. Wu, Z. Xiang, G. Huang, et al., “BGN/FAP/STAT3 Positive Feedback Loop Mediated Mutual Interaction Between Tumor Cells and Mesothelial Cells Contributes to Peritoneal Metastasis of Gastric Cancer,” International Journal of Biological Sciences 19, no. 2 (2023): 465-83.

[178] H. Zhang, X. Zhu, T. J. Friesen, et al., “Annexin A2/TLR2/MYD88 Pathway Induces Arginase 1 Expression in Tumor-Associated Neutrophils,” Journal of Clinical Investigation 132, no. 22 (2022): e153643.

[179] F. M. Abdallah, A. I. Ghoneim, M. M. Abd-Alhaseeb, I. T. Abdel-Raheem, M. W. Helmy, “Unveiling the Antitumor Synergy Between Pazopanib and Metformin on Lung Cancer Through Suppressing p-Akt/NF-κB/ STAT3/ PD-L1 Signal Pathway,” Biomedicine & Pharmacotherapy 180 (2024): 117468.

[180] A. Di Lorenzo, E. Bolli, R. Ruiu, et al., “Toll-Like Receptor 2 Promotes Breast Cancer Progression and Resistance to Chemotherapy,” Oncoimmunology 11, no. 1 (2022): 2086752.

[181] B. Liu, J. Huang, J. Xiao, et al., “The Streptococcus Virulence Protein PepO Triggers Anti-Tumor Immune Responses by Reprograming Tumor-Associated Macrophages in a Mouse Triple Negative Breast Cancer Model,” Cell & Bioscience 13, no. 1 (2023): 198.

[182] R. Liu, G. Zhu, Y. Sun, et al., “Neutrophil Infiltration Associated Genes on the Prognosis and Tumor Immune Microenvironment of Lung Adenocarcinoma,” Frontiers in Immunology 14 (2023): 1304529.

[183] S. Maijaroen, S. Klaynongsruang, S. Reabroi, et al., “Proteomic Profiling Reveals Antitumor Effects of RT2 Peptide on a Human Colon Carcinoma Xenograft Mouse Model,” European Journal of Pharmacology 917 (2022): 174753.

[184] X. Man, J. Huang, S. Sun, et al., “Efficacy and Safety of Pyrotinib Combined With Albumin-Bound Paclitaxel as First-Line Treatment for HER2-Positive Metastatic Breast Cancer in Patients Previously Treated With Adjuvant and/or Neoadjuvant Trastuzumab Therapy: The Stage 1 Results of a Single-Arm, Phase 2 Prospective Clinical Trial,” Clinical and Translational Medicine 14, no. 5 (2024): e1687.

[185] S. Gandhi, M. Opyrchal, M. J. Grimm, et al., “Systemic Infusion of TLR3-Ligand and IFN-α in Patients With Breast Cancer Reprograms Local Tumor Microenvironments for Selective CTL Influx,” Journal for ImmunoTherapy of Cancer 11, no. 11 (2023).

[186] L. Huang, Y. Rong, X. Tang, et al., “Engineered Exosomes as an in Situ DC-Primed Vaccine to Boost Antitumor Immunity in Breast Cancer,” Molecular Cancer 21, no. 1 (2022): 45.

[187] J. Mannion, V. Gifford, B. Bellenie, et al., “A RIPK1-Specific PROTAC Degrader Achieves Potent Antitumor Activity by Enhancing Immunogenic Cell Death,” Immunity 57, no. 7 (2024): 1514-32.e15.

[188] H. E. Ramsey, A. E. Gorska, B. N. Smith, et al., “TLR3 Agonism Augments CD47 Inhibition in Acute Myeloid Leukemia,” Haematologica 109, no. 7 (2024): 2111-21.

[189] M. J. Kim, Y. Min, S. K. Jeong, et al., “USP15 Negatively Regulates Lung Cancer Progression Through the TRAF6-BECN1 Signaling Axis for Autophagy Induction,” Cell Death & Disease 13, no. 4 (2022): 348.

[190] H. Lu, X. Xu, D. Fu, et al., “Butyrate-Producing Eubacterium Rectale Suppresses Lymphomagenesis by Alleviating the TNF-Induced TLR4/MyD88/NF-κB Axis,” Cell Host & Microbe 30, no. 8 (2022): 1139-50.e7.

[191] Y. Du, Y. Cai, Y. Lv, et al., “Single-Cell RNA Sequencing Unveils the Communications Between Malignant T and Myeloid Cells Contributing to Tumor Growth and Immunosuppression in Cutaneous T-Cell Lymphoma,” Cancer Letters 551 (2022): 215972.

[192] X. Kang, C. Liu, Y. Ding, et al., “Roseburia Intestinalis Generated Butyrate Boosts Anti-PD-1 Efficacy in Colorectal Cancer by Activating Cytotoxic CD8(+) T Cells,” Gut 72, no. 11 (2023): 2112-22.

[193] A. Ambesi, P. Maddali, P. J. McKeown-Longo, “Fibronectin Functions as a Selective Agonist for Distinct Toll-Like Receptors in Triple-Negative Breast Cancer,” Cells 11, no. 13 (2022): 2074.

[194] V. Padmanaban, I. Keller, E. S. Seltzer, B. N. Ostendorf, Z. Kerner, S. F. Tavazoie, “Neuronal Substance P Drives Metastasis Through an Extracellular RNA-TLR7 Axis,” Nature 633, no. 8028 (2024): 207-15.

[195] Y. T. Wei, X. R. Wang, C. Yan, et al., “Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages During Efferocytosis,” Cancer Research 82, no. 10 (2022): 1991-2002.

[196] Z. Jiang, G. Cai, H. Liu, et al., “A Combination of a TLR7/8 Agonist and an Epigenetic Inhibitor Suppresses Triple-Negative Breast Cancer Through Triggering Anti-Tumor Immune,” Journal of Nanobiotechnology 22, no. 1 (2024): 296.

[197] X. Zuo, Q. Cheng, Z. Wang, et al., “A Novel Oral TLR7 Agonist Orchestrates Immune Response and Synergizes With PD-L1 Blockade via Type I IFN Pathway in Lung Cancer,” International Immunopharmacology 137 (2024): 112478.

[198] M. Wang, Q. Wan, C. Wang, et al., “Combinational Delivery of TLR4 and TLR7/8 Agonist Enhanced the Therapeutic Efficacy of Immune Checkpoint Inhibitors to Colon Tumor,” Molecular and Cellular Biochemistry 480, no. 1 (2025): 445-58.

[199] W. Yang, X. Sun, S. Liu, et al., “TLR8 Agonist Motolimod-Induced Inflammatory Death for Treatment of Acute Myeloid Leukemia,” Biomedicine & Pharmacotherapy 163 (2023): 114759.

[200] S. Ceccarelli, V. Pasqua Marzolesi, J. Vannucci, et al., “Toll-Like Receptor 4 and 8 Are Overexpressed in Lung Biopsies of Human Non-Small Cell Lung Carcinoma,” Lung 203, no. 1 (2025): 38.

[201] J. Smok-Kalwat, P. Mertowska, S. Mertowski, S. Góźdź, E. Grywalska, “Toll-Like Receptors: Key Players in Squamous Cell Carcinoma Progression,” Journal of Clinical Medicine 13, no. 15 (2024): 4531.

[202] S. Hajiabadi, S. Alidadi, Z. Montakhab Farahi, M. M. Ghahramani Seno, H. Farzin, A. Haghparast, “Immunotherapy With STING and TLR9 Agonists Promotes Synergistic Therapeutic Efficacy With Suppressed Cancer-Associated Fibroblasts in Colon Carcinoma,” Frontiers in Immunology 14 (2023): 1258691.

[203] K. C. Huang, C. Y. Lai, W. Z. Hung, et al., “A Novel Engineered AAV-Based Neoantigen Vaccine in Combination With Radiotherapy Eradicates Tumors,” Cancer Immunology Research 11, no. 1 (2023): 123-36.

[204] M. Jing, L. Qiong, Z. Wang, X. Xiong, Y. Fu, W. Yan, “Histone H3 Activates Caspase-1 and Promotes Proliferation and Metastasis in Hepatocellular Carcinoma,” International Journal of Medical Sciences 20, no. 5 (2023): 689-701.

[205] Z. Liu, S. Shan, Z. Yuan, et al., “Mitophagy Bridges DNA Sensing With Metabolic Adaption to Expand Lung Cancer Stem-Like Cells,” EMBO Reports 24, no. 2 (2023): e54006.

[206] P. Zhang, T. Wang, G. Cui, et al., “Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia,” Advanced Materials 36, no. 40 (2024): e2407189.

[207] F. Exposito, M. Redrado, M. Houry, et al., “PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells,” Cancer Research 83, no. 15 (2023): 2513-26.

[208] E. Jung, Y. H. Chung, N. F. Steinmetz, “TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy,” Bioconjugate Chemistry 34, no. 9 (2023): 1596-605.

[209] A. M. Eckhoff, M. C. Brown, K. Landa, et al., “Functional Reprogramming of Peripheral Blood Monocytes by Soluble Mediators in Patients With Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms,” Frontiers in Immunology 14 (2023): 1116034.

[210] D. M. Klinman, E. Goguet, D. Tross, “TLR Agonist Therapy of Metastatic Breast Cancer in Mice,” Journal of Immunotherapy 46, no. 5 (2023): 170-7.

[211] P. Korangath, L. Jin, C. T. Yang, et al., “Iron Oxide Nanoparticles Inhibit Tumor Progression and Suppress Lung Metastases in Mouse Models of Breast Cancer,” ACS Nano 18, no. 15 (2024): 10509-26.

[212] N. Chernyak, B. Bhagwat, S. Naravula, et al., “Discovery and Evaluation of TLR-Targeted Immune Agonists,” Journal of Medicinal Chemistry 67, no. 18 (2024): 16222-34.

[213] J. Gallardo-Zapata, E. Pérez-Figueroa, V. Olivar-López, et al., “TLR Agonists Modify NK Cell Activation and Increase Its Cytotoxicity in Acute Lymphoblastic Leukemia,” International Journal of Molecular Sciences 25, no. 13 (2024): 7500.

[214] A. Kuipery, J. D. Sanchez Vasquez, A. Mehrotra, J. J. Feld, H. L. A. Janssen, A. J. Gehring, “Immunomodulation and RNA Interference Alter Hepatitis B Virus-Specific CD8 T-Cell Recognition of Infected HepG2-NTCP,” Hepatology 75, no. 6 (2022): 1539-50.

[215] T. Mori, S. Yoshio, S. Yoshikawa, et al., “Toll-Like Receptor 7 Agonist, GS-986, Is an Immune-Stimulant Inducing Follicular Helper T Cells and Expanding HBs Antigen-Specific B Cells in Vitro,” Liver International 43, no. 6 (2023): 1213-24.

[216] S. Park, G. Kim, A. Choi, et al., “Comparative Network-Based Analysis of Toll-Like Receptor Agonist, L-Pampo Signaling Pathways in Immune and Cancer Cells,” Scientific Reports 14, no. 1 (2024): 17173.

[217] J. Liu, C. Ding, X. Wang, L. Yang, X. Liu, Q. Kang, “TLR Agonist rMBP-NAP Inhibits B16 Melanoma Tumor Growth via Induction of DCs Maturation and T-Cells Cytotoxic Response,” Cytotechnology 74, no. 4 (2022): 459-67.

[218] C. W. F. van Eijck, H. E. Haddaoui, S. Kucukcelebi, et al., “Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity Through Dendritic Cell-Mediated T-Cell Responses,” Clinical Cancer Research 30, no. 16 (2024): 3447-58.

[219] A. K. Ajay, M. Gasser, L. L. Hsiao, T. Böldicke, A. M. Waaga-Gasser, “TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth,” Antibodies (Basel) 13, no. 1 (2024): 11.

[220] I. Takahashi, K. Takagi, M. Yamaguchi-Tanaka, et al., “Toll-Like Receptor (TLR) 4 Is a Potent Prognostic Factor in Prostate Cancer Associated With Proliferation and Invasion,” Pathology, Research and Practice 260 (2024): 155379.

[221] X. Tian, K. Nanding, X. Dai, et al., “Pattern Recognition Receptor Mediated Innate Immune Response Requires a Rif-Dependent Pathway,” Journal of Autoimmunity 134 (2023): 102975.

[222] M. Sezaki, G. Huang, “Repurposing Immunosuppressants for Antileukemia Therapy,” EMBO Molecular Medicine 15, no. 1 (2023): e17042.

[223] X. Liu, N. Sato, T. Yabushita, et al., “IMPDH Inhibition Activates TLR-VCAM1 Pathway and Suppresses the Development of MLL-Fusion Leukemia,” EMBO Molecular Medicine 15, no. 1 (2023): e15631.

[224] Y. Wei, G. Qin, Z. Wang, C. Zhao, J. Ren, X. Qu, “Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade,” ACS Nano 17, no. 6 (2023): 5808-20.

[225] S. Shen, Y. Cui, M. Li, et al., “TLR Agonists Promote Formation of Tertiary Lymphoid Structure and Improve Anti-Glioma Immunity,” Neuro-Oncology 27, no. 1 (2024): 140-54.

[226] B. C. Zhang, C. M. Lai, B. Y. Luo, J. W. Shao, “Triterpenoids-Templated Self-Assembly Nanosystem for Biomimetic Delivery of CRISPR/Cas9 Based on the Synergy of TLR-2 and ICB to Enhance HCC Immunotherapy,” Acta Pharm Sin B 14, no. 7 (2024): 3205-17.

[227] Y. Wu, Z. Yang, K. Cheng, H. Bi, J. Chen, “Small Molecule-Based Immunomodulators for Cancer Therapy,” Acta Pharm Sin B 12, no. 12 (2022): 4287-308.

[228] G. Guney Eskiler, A. Deveci Özkan, “The Relationship Between the Efficacy of Talazoparib and the Functional Toll-Like Receptors 3 and 9 in Triple Negative Breast Cancer,” Molecular Immunology 141 (2022): 280-6.

[229] L. He, J. Zhao, H. Li, et al., “Metabolic Reprogramming of NK Cells by Black Phosphorus Quantum Dots Potentiates Cancer Immunotherapy,” Advanced Science (Weinh) 10, no. 8 (2023): e2202519.

[230] D. Taylor, C. T. Meyer, D. Graves, et al., “MuSyC Dosing of Adjuvanted Cancer Vaccines Optimizes Antitumor Responses,” Frontiers in Immunology 13 (2022): 936129.

[231] B. Wang, Z. Ou, W. Zhong, et al., “Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination With a TLR3-Specific Adjuvant,” Cancer Immunology Research 11, no. 12 (2023): 1656-70.

[232] S. Taghiloo, A. Ajami, R. Alizadeh-Navaei, H. Asgarian-Omran, “Combination Therapy of Acute Myeloid Leukemia by Dual PI3K/mTOR Inhibitor BEZ235 and TLR-7/8 Agonist R848 in Murine Model,” International Immunopharmacology 125, no. Pt B (2023): 111211.

[233] A. El-Obeid, Y. Maashi, R. AlRoshody, et al., “Herbal Melanin Modulates PGE2 and IL-6 Gastroprotective Markers Through COX-2 and TLR4 Signaling in the Gastric Cancer Cell Line AGS,” BMC Complementary Medicine and Therapies 23, no. 1 (2023): 305.

[234] Y. Xun, H. Yang, B. Kaminska, H. You, “Toll-Like Receptors and Toll-Like Receptor-Targeted Immunotherapy Against Glioma,” Journal of Hematology & Oncology 14, no. 1 (2021): 176.

[235] Y. Hao, H. Li, X. Ge, et al., “Site-Specific Nanoswitch Circumventing Immune Resistance via Activating TLR and Inhibiting PD-L1/PD-1 Axis,” Journal of Controlled Release 361 (2023): 64-76.

[236] H. Kim, V. Khanna, T. A. Kucaba, et al., “Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine,” Molecular Pharmaceutics 16, no. 3 (2019): 1200-10.

[237] D. Jeon, E. Hill, J. E. Moseman, D. G. McNeel, “Combining Toll-Like Receptor Agonists With Immune Checkpoint Blockade Affects Antitumor Vaccine Efficacy,” Journal for ImmunoTherapy of Cancer 12, no. 5 (2024): e008799.

[238] S. Singh, J. Roszik, N. Saini, et al., “B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade,” Frontiers in Immunology 13 (2022): 794684.

[239] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, E. Charpentier, “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,” Science 337, no. 6096 (2012): 816-21.

[240] Z. Zuo, A. K. Kania, D. G. Patterson, et al., “CRISPR/Cas9 Editing Reveals IRF8 Regulated Gene Signatures Restraining Plasmablast Differentiation,” Heliyon 9, no. 6 (2023): e17527.

[241] D. F. Selgrade, D. E. Fullenkamp, I. A. Chychula, et al., “Susceptibility to Innate Immune Activation in Genetically Mediated Myocarditis,” Journal of Clinical Investigation 134, no. 13 (2024).

[242] N. Al Fayez, E. Rouhollahi, C. Y. Ong, et al., “Hepatocyte-Targeted Delivery of Imiquimod Reduces Hepatitis B Virus Surface Antigen,” Journal of Controlled Release 350 (2022): 630-41.

[243] J. Stickdorn, L. Stein, D. Arnold-Schild, et al., “Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses Against Tumors,” ACS Nano 16, no. 3 (2022): 4426-43.

[244] R. Li, X. Huang, X. Li, H. Liu, J. Zhou, J. Shen, “A Multi-Functional Drug Delivery Nanosystem Release of TLR-7 Immunostimulant and OKT3 Induced Efficient Cancer Immunotherapy,” Photodiagnosis and Photodynamic Therapy 44 (2023): 103834.

[245] R. Chang, X. Chu, J. Zhang, et al., “Liposome-Based Co-Immunotherapy With TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer,” Molecules (Basel, Switzerland) 28, no. 7 (2023): 3147.

[246] B. L. Nguyen, C. D. Phung, D. V. Pham, et al., “Liposomal Co-Delivery of Toll-Like Receptors 3 and 7 Agonists Induce a Hot Triple-Negative Breast Cancer Immune Environment,” Journal of Controlled Release 361 (2023): 443-54.

[247] C. Anfray, C. F. Varela, A. Ummarino, et al., “Polymeric Nanocapsules Loaded With Poly(I:C) and Resiquimod to Reprogram Tumor-Associated Macrophages for the Treatment of Solid Tumors,” Frontiers in Immunology 14 (2023): 1334800.

[248] J. Wan, L. Ren, X. Li, et al., “Photoactivatable Nanoagonists Chemically Programmed for Pharmacokinetic Tuning and in Situ Cancer Vaccination,” PNAS 120, no. 8 (2023): e2210385120.

[249] X. Jiang, J. Liu, M. J. Lee, et al., “Nanoscale Coordination Polymer Synergizes Photodynamic Therapy and Toll-Like Receptor Activation for Enhanced Antigen Presentation and Antitumor Immunity,” Biomaterials 302 (2023): 122334.

[250] K. S. Maravajjala, K. L. Swetha, A. Roy, “pH-Responsive Nanoparticles for Multidimensional Combined Chemo-Immunotherapy of Cancer,” Journal of Pharmaceutical Sciences 111, no. 8 (2022): 2353-68.

[251] Y. Jia, K. Shi, L. Dai, et al., “Gold Nanorods and Polymer Micelles Mediated Dual TLR Stimulators Delivery System CPG@Au NRs/M-R848 Regulate Macrophages Reprogramming and DC Maturation for Enhanced Photothermal Immunotherapy of Melanoma,” Small Methods 7, no. 5 (2023): e2201087.

[252] Y. Liu, C. Li, H. Xia, et al., “An Injectable Superior Depot of Telratolimod Inhibits Post-Surgical Tumor Recurrence and Distant Metastases,” Acta Biomaterialia 141 (2022): 132-9.

[253] M. Pei, H. Li, Y. Zhu, J. Lu, C. Zhang, “In Vitro Evidence of Oncofetal Antigen and TLR-9 Agonist Co-Delivery by Alginate Nanovaccines for Liver Cancer Immunotherapy,” Biomaterials Science 10, no. 11 (2022): 2865-76.

[254] N. K. Wolf, C. Blaj, L. K. Picton, et al., “Synergy of a STING Agonist and an IL-2 Superkine in Cancer Immunotherapy Against MHC I-Deficient and MHC I(+) Tumors,” PNAS 119, no. 22 (2022): e2200568119.

[255] Y. Wang, S. L. Qiao, J. Wang, et al., “Engineered CpG-Loaded Nanorobots Drive Autophagy-Mediated Immunity for TLR9-Positive Cancer Therapy,” Advanced Materials 36, no. 22 (2024): e2306248.

[256] S. Huang, Y. Gao, H. Li, et al., “Manganese@Albumin Nanocomplex and Its Assembled Nanowire Activate TLR4-Dependent Signaling Cascades of Macrophages,” Advanced Materials 36, no. 5 (2024): e2310979.

[257] S. Padma, R. Patra, P. S. Sen Gupta, S. K. Panda, M. K. Rana, S. Mukherjee, “Cell Surface Fibroblast Activation Protein-2 (Fap2) of Fusobacterium Nucleatum as a Vaccine Candidate for Therapeutic Intervention of Human Colorectal Cancer: An Immunoinformatics Approach,” Vaccines (Basel) 11, no. 3 (2023): 525.

[258] M. C. Sellars, C. J. Wu, E. F. Fritsch, “Cancer Vaccines: Building a Bridge Over Troubled Waters,” Cell 185, no. 15 (2022): 2770-88.

[259] P. Guasp, C. Reiche, Z. Sethna, V. P. Balachandran, “RNA Vaccines for Cancer: Principles to Practice,” Cancer Cell 42, no. 7 (2024): 1163-84.

[260] E. Furlong, R. S. Kotecha, “Lessons Learnt From Influenza Vaccination in Immunocompromised Children Undergoing Treatment for Cancer,” Lancet Child Adolesc Health 7, no. 3 (2023): 199-213.

[261] R. Pascolutti, L. Yeturu, G. Philippin, et al., “ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways Through TLR4 and TLR2 in Human Monocytes and Dendritic Cells,” Cancers (Basel) 14, no. 20 (2022): 5134.

[262] J. Ma, S. Wang, C. Zhao, et al., “Computer-Aided Discovery of Potent Broad-Spectrum Vaccine Adjuvants,” Angewandte Chemie (International ed in English) 62, no. 18 (2023): e202301059.

[263] H. Song, Q. Su, W. Shi, et al., “Antigen Epitope-TLR7/8a Conjugate as Self-Assembled Carrier-Free Nanovaccine for Personalized Immunotherapy,” Acta Biomaterialia 141 (2022): 398-407.

[264] A. Arabi, S. Aria Soltani, B. Maniaci, K. Mann, H. Martinson, M. Kullberg, “Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice Through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes,” Pharmaceutics 15, no. 12 (2023): 2774.

[265] E. Jahangirian, G. A. Jamal, M. Nouroozi, A. Mohammadpour, “A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches,” International Journal of Peptide Research and Therapeutics 28, no. 2 (2022): 71.

[266] M. H. U. Masum, S. Wajed, M. I. Hossain, N. R. Moumi, A. Talukder, M. M. Rahman, “An mRNA Vaccine for Pancreatic Cancer Designed by Applying in Silico Immunoinformatics and Reverse Vaccinology Approaches,” PLoS ONE 19, no. 7 (2024): e0305413.

[267] Y. Gu, J. Yang, C. He, et al., “Incorporation of a Toll-Like Receptor 2/6 Agonist Potentiates mRNA Vaccines Against Cancer and Infectious Diseases,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 273.

[268] H. E. Haddaoui, C. W. van Eijck, M. Doukas, et al., “Rintatolimod: A Potential Treatment in Patients With Pancreatic Cancer Expressing Toll-Like Receptor 3,” American Journal of Cancer Research 13, no. 6 (2023): 2657-69.

[269] L. A. Zúñiga, T. Leßmann, K. Uppal, et al., “Intratumoral Delivery of TransCon(™) TLR7/8 Agonist Promotes Sustained Anti-Tumor Activity and Local Immune Cell Activation While Minimizing Systemic Cytokine Induction,” Cancer Cell International 22, no. 1 (2022): 286.

[270] J. A. B. Scutti, L. M. Vence, R. E. Royal, et al., “Abstract 614: Resiquimod, a Toll-Like Receptor Agonist Promotes Melanoma Regression by Enhancing Plasmacytoid Dendritic Cells and T Cytotoxic Activity as a Vaccination Adjuvant and by Direct Tumor Application,” Cancer Research 78, no. 13-Sup (2018): 1.

[271] L. Siu, J. Brody, S. Gupta, et al., “Safety and Clinical Activity of Intratumoral MEDI9197 Alone and in Combination With Durvalumab and/or Palliative Radiation Therapy in Patients With Advanced Solid Tumors,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e001095.

[272] E. Wolf, G. Sacchi de Camargo Correia, S. Li, Y. Zhao, R. Manochakian, Y. Lou, “Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer,” Vaccines (Basel) 13, no. 2 (2025): 128.

[273] S. P. Patel, G. R. Petroni, J. Roszik, et al., “Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus Toll-Like Receptor (TLR) Agonists With or Without Incomplete Freund's Adjuvant (IFA) for Resected High-Risk Melanoma,” Journal for ImmunoTherapy of Cancer 9, no. 8 (2021): e003220.

[274] D. A. Ruiz-Torres, J. F. Wise, B. Y. Zhao, “Dendritic Cell Effector Mechanisms and Tumor Immune Microenvironment Infiltration Define TLR8 Modulation and PD-1 Blockade,” Frontiers in Immunology 15 (2024): 1440530.

[275] R. G. Everson, W. Hugo, L. Sun, et al., “TLR Agonists Polarize Interferon Responses in Conjunction With Dendritic Cell Vaccination in Malignant Glioma: A Randomized Phase II Trial,” Nature Communications 15, no. 1 (2024): 3882.

[276] S. Adams, S. Demaria, D. Rinchai, et al., “Topical TLR7 Agonist and Radiotherapy in Patients With Metastatic Breast Cancer,” Journal for ImmunoTherapy of Cancer 13, no. 4 (2025): e011173.

[277] M. O. Meneveau, G. R. Petroni, E. P. Salerno, et al., “Immunogenicity in Humans of a Transdermal Multipeptide Melanoma Vaccine Administered With or Without a TLR7 Agonist,” Journal for ImmunoTherapy of Cancer 9, no. 5 (2021): e002214.

[278] A. J. Yoon, R. D. Carvajal, E. M. Graboyes, et al., “Pilot Clinical Trial of Neoadjuvant Toll-Like Receptor 7 Agonist (Imiquimod) Immunotherapy in Early-Stage Oral Squamous Cell Carcinoma,” Frontiers in Immunology 16 (2025): 1530262.

[279] S. P. Chawla, B. A. Van Tine, S. M. Pollack, et al., “Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1,” Journal of Clinical Oncology 40, no. 12 (2022): 1291-300.

[280] C. L. Slingluff, H. M. Zarour, H. A. Tawbi, et al., “A Phase 1 Study of NY-ESO-1 Vaccine + Anti-CTLA4 Antibody Ipilimumab (IPI) in Patients With Unresectable or Metastatic Melanoma,” Oncoimmunology 10, no. 1 (2021): 1898105.

[281] T. Ishikawa, S. Kageyama, Y. Miyahara, et al., “Safety and Antibody Immune Response of CHP-NY-ESO-1 Vaccine Combined With Poly-ICLC in Advanced or Recurrent Esophageal Cancer Patients,” Cancer Immunology, Immunotherapy 70, no. 11 (2021): 3081-91.

[282] A. Pavlick, A. B. Blazquez, M. Meseck, et al., “Combined Vaccination With NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients With High-Risk Melanoma,” Cancer Immunology Research 8, no. 1 (2020): 70-80.

[283] G. Curigliano, M. M. Jimenez, T. Shimizu, et al., “A Phase I Trial of LHC165 Single Agent and in Combination With Spartalizumab in Patients With Advanced Solid Malignancies,” ESMO Open 9, no. 8 (2024): 103643.

[284] S. Mukherjee, R. Patra, P. Behzadi, A. Masotti, A. Paolini, M. Sarshar, “Toll-Like Receptor-Guided Therapeutic Intervention of Human Cancers: Molecular and Immunological Perspectives,” Frontiers in Immunology 14 (2023): 1244345.

[285] Y. Zhou, H. M. Song, “Type I Interferon Pathway in Pediatric Systemic Lupus Erythematosus,” World Journal of Pediatrics 20, no. 7 (2024): 653-68.

[286] S. Yang, F. Humphries, “Emerging Roles of ECSIT in Immunity and Tumorigenesis,” Trends in Cell Biology 35, no. 5 (2025): 426-438.

[287] L. Yang, A. Li, Y. Wang, Y. Zhang, “Intratumoral Microbiota: Roles in Cancer Initiation, Development and Therapeutic Efficacy,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 35.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.